Skip to Main Content
Back to News

$RNA stock is up 42% today. Here's what we see in our data.

None

$RNA stock has now risen 42% today, according to our price data from Polygon. There has been approximately $2,028,000,100 of trading volume.

Here is what we see in our data on $RNA (you can track the company live on Quiver's $RNA stock page):

$RNA Insider Trading Activity

RNA Insider Trades

$RNA insiders have traded $RNA stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.

Here’s a breakdown of recent trading of $RNA stock by insiders over the last 6 months:

  • ERIC MOSBROOKER (Chief Commercial Officer) has made 0 purchases and 4 sales selling 143,932 shares for an estimated $6,370,403.
  • TROY EDWARD WILSON has made 0 purchases and 8 sales selling 124,554 shares for an estimated $5,752,430.
  • ARTHUR A LEVIN sold 107,500 shares for an estimated $5,118,881
  • STEVEN GEORGE HUGHES (Chief Medical Officer) has made 0 purchases and 10 sales selling 91,143 shares for an estimated $3,919,317.
  • SARAH BOYCE (President and CEO) has made 0 purchases and 2 sales selling 75,000 shares for an estimated $3,732,135.
  • TERESA MCCARTHY (Chief Human Resources Officer) has made 0 purchases and 3 sales selling 45,000 shares for an estimated $2,089,832.
  • W. MICHAEL FLANAGAN (Chief Scientific Officer) has made 0 purchases and 2 sales selling 40,000 shares for an estimated $1,436,396.
  • MICHAEL F MACLEAN (Chief Financial Officer) sold 30,914 shares for an estimated $1,320,843
  • KATHLEEN P. GALLAGHER (Chief Program Officer) has made 0 purchases and 4 sales selling 12,849 shares for an estimated $417,620.
  • JOHN B MORIARTY (Chief Legal Officer) sold 2,245 shares for an estimated $81,291

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$RNA Hedge Fund Activity

We have seen 128 institutional investors add shares of $RNA stock to their portfolio, and 108 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RNA Analyst Ratings

Wall Street analysts have issued reports on $RNA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • B of A Securities issued a "Buy" rating on 09/15/2025
  • Chardan Capital issued a "Buy" rating on 09/10/2025
  • Barclays issued a "Overweight" rating on 08/08/2025
  • Wells Fargo issued a "Overweight" rating on 08/08/2025
  • Goldman Sachs issued a "Buy" rating on 07/10/2025
  • Cantor Fitzgerald issued a "Overweight" rating on 06/27/2025
  • Wolfe Research issued a "Outperform" rating on 06/17/2025

To track analyst ratings and price targets for $RNA, check out Quiver Quantitative's $RNA forecast page.

$RNA Price Targets

Multiple analysts have issued price targets for $RNA recently. We have seen 15 analysts offer price targets for $RNA in the last 6 months, with a median target of $65.0.

Here are some recent targets:

  • Ananda Ghosh from HC Wainwright & Co. set a target price of $72.0 on 10/27/2025
  • Joseph Stringer from Needham set a target price of $65.0 on 10/27/2025
  • William Pickering from Bernstein set a target price of $72.0 on 10/27/2025
  • Josh Schimmer from Evercore ISI Group set a target price of $65.0 on 09/22/2025
  • Boobalan Pachaiyappan from Roth Capital set a target price of $62.0 on 09/17/2025
  • Geoff Meacham from B of A Securities set a target price of $65.0 on 09/15/2025
  • Keay Nakae from Chardan Capital set a target price of $75.0 on 09/10/2025

You can track data on $RNA on Quiver Quantitative.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles